TraceLink: Digital Network Platform to Further Transform the Global Pharmaceutical Supply Chain

Healthcare Packaging | October 17, 2019

TraceLink: Digital Network Platform to Further Transform the Global Pharmaceutical Supply Chain
TraceLink, an integrated digital supply network, announces the launch of the Digital Network Platform. Built on top of the TraceLink Digital Supply Network, and designed for the rapid development of applications utilizing its multi-enterprise collaboration and data sharing capabilities, TraceLink’s Digital Network Platform is meant to drive innovation and enable the creation of new supply chain operating models centered around the patient. The TraceLink network is used to track serialized medicines as they move from production to the patient. With the launch of the Digital Network Platform, TraceLink customers will be supposed to have access to a new class of network orchestration and analytics applications in order to unlock even more value from their digitalized supply chains and provide the power to orchestrate patient outcomes in new ways.

Spotlight

The artificial intelligence (AI) healthcare market is expected reach $6.6 billion by 2021, representing a compound annual growth rate (CAGR) of 40 percent over the next five years, according to a report from Accenture. AI in health represents a collection of multiple technologies enabling machines to sense, comprehend, act and learn so they can perform administrative and clinical healthcare functions. Unlike legacy technologies that are only algorithms/ tools that complement a human, health AI today can truly augment human activity.

Related News

BUSINESS INSIGHTS

Cyclenium Pharma and Vuja De Sciences Announce Oncology Drug Discovery Collaboration

Cyclenium Pharma | January 06, 2022

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will screen and optimize lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence, the biggest unmet need in oncology. The collaboration will exploit Vuja De’s proprietary anti-metastatic progression in vitro and ex vivo drug discovery screening platform and Cyclenium’s proprietary QUEST™ Library of next generation synthetic small-molecule macrocycles and associated optimization expertise to identify clinical candidates effective against dormant disseminated tumor cells for the prevention of metastatic cancer recurrence. Vuja De will be responsible for all screening efforts, while Cyclenium will be responsible for all medicinal chemistry efforts to generate new optimized macrocyclic compounds by employing its unique CMRT™ Technology. “We are very excited about entering this collaboration with Vuja De. We are confident that our CMRT™ Technology and proven success in the macrocycle area combined with the innovative anti-metastatic progression platform and excellent research team at Vuja De will enable the discovery and development of novel macrocyclic therapeutic agents to effectively control metastatic progression.” Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer of Cyclenium “We highly appreciate Cyclenium’s expertise in the macrocycle area and their technology platform that is based on over 20 years of pioneering experience in small molecule macrocyclic chemistry,” said David Warshawsky, Ph.D., Chief Executive Officer of Vuja De. “We are very pleased to work with Cyclenium on identifying and developing novel game-changing drug candidates that prevent metastatic recurrence, the most urgent need of most cancer patients,” he added. About Cyclenium Pharma Cyclenium Pharma is an emerging, privately held pharmaceutical research and development company exploiting its proprietary next generation CMRT™ macrocyclic drug discovery technology for the discovery and development of novel small molecule therapeutic agents to address areas of unsatisfied medical need. Cyclenium is creating value through progression of internal programs in oncology, infectious diseases and inflammation/pain. In addition, Cyclenium is providing its extensive experience and exploring its CMRT-based QUEST™ screening library in risk-sharing partnerships with leading academic and research driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies world-wide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. About Vuja De Sciences Vuja De is a biotechnology startup company dedicated to discovering and developing therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence. This vulnerability of DTCs stems from their dependence on a unique phenotype that includes stress adaptation, survival & dormancy, which we have coined “Metastatic Endurance”. ME enables DTCs to persist undetected at secondary sites like “ticking time-bombs” and eventually start to rapidly divide and form overt deadly tumors. We successfully created the first-ever cell-based and ex vivo drug screening platform that finds drugs that target ME. We are using the largely adolescent, orphan disease, osteosarcoma, as the best proof of concept model for developing anti metastatic progression drugs for many cancers such as breast, melanoma and kidney. We are testing repurposed drugs that have previously been in clinical trials, as well as novel preclinical drugs. About Osteosarcoma Osteosarcoma is an aggressive cancer of the bone and is the most common type of bone cancer in children and teens. Since metastatic recurrence has shared biological mechanism in many other cancer types, therapies that show promise in osteosarcoma can be developed in parallel for many other cancer types, such as breast, kidney and melanoma. Despite successful control of the primary osteosarcoma tumors and follow-up chemotherapy, metastasis continues to be the most common cause of mortality. The last 30 years have brought little improvement in survival outcomes for children with osteosarcoma, despite intensification of therapy. Due to lack of improved outcomes, new approaches to therapy are highly needed. Furthermore, if targeted therapeutics are found to prevent metastasis in this cancer, a strong biological rationale would exist for the evaluation of such a therapy in other human cancers.

Read More

Alliance for Regenerative Medicine Published its Response to EU Pharmaceutical Roadmap

Alliance for Regenerative Medicine | July 07, 2020

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While ARM welcomes the Roadmap’s recognition of the wider industry’s contribution to the EU economy and its focus on ensuring patients’ access to safe, state-of-the-art therapies, ARM wants to ensure a continued pathway for the EU to benefit from innovative and life-changing advanced therapy medicinal products (ATMPs).

Read More

Allied Expands Pharmaceutical Pipeline By Filing US Provisional Patent for Psilocybin Based Therapeutics

Allied Corp | October 21, 2020

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety. Psilocybin is the active pharmaceutical ingredient contained in the Golden Teacher psychedelic mushroom. Along with the novel treatment regimen, Allied’s formulation consists of novel micro-dose ratios of several medical mushroom compounds combined with additional natural health molecules.

Read More

Spotlight

The artificial intelligence (AI) healthcare market is expected reach $6.6 billion by 2021, representing a compound annual growth rate (CAGR) of 40 percent over the next five years, according to a report from Accenture. AI in health represents a collection of multiple technologies enabling machines to sense, comprehend, act and learn so they can perform administrative and clinical healthcare functions. Unlike legacy technologies that are only algorithms/ tools that complement a human, health AI today can truly augment human activity.